Last reviewed · How we verify
moracizine
moracizine is a drug. It is currently in unknown development for Ventricular arrhythmia.
At a glance
| Generic name | moracizine |
|---|---|
| Target | Sodium channel protein type 5 subunit alpha |
| Therapeutic area | Cardiovascular |
| Phase | unknown |
Approved indications
- Ventricular arrhythmia
Common side effects
Key clinical trials
- NCT00000526 (Phase 3)
- NCT00000556 (Phase 3)
- NCT00000504 (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- moracizine CI brief — competitive landscape report
- moracizine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about moracizine
What is moracizine?
moracizine is a pharmaceutical drug, indicated for Ventricular arrhythmia.
What is moracizine used for?
moracizine is indicated for Ventricular arrhythmia.
What development phase is moracizine in?
moracizine is in unknown.
What does moracizine target?
moracizine targets Sodium channel protein type 5 subunit alpha.
Related
- Target: All drugs targeting Sodium channel protein type 5 subunit alpha
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Ventricular arrhythmia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing